Neurosearch Pushes on with Huntington's Disease Drug
By Nuala Moran
Tuesday, January 4, 2011
LONDON Neurosearch said it intends to press ahead and present the data on its Huntington's disease treatment Huntexil (pridopine) to regulators, following a meta-analysis of two studies that each individually failed to meet the primary endpoint.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.